The relationship between mindfulness, pain intensity, pain catastrophizing, depression, and quality of life among cancer survivors living with chronic neuropathic pain

Patricia A. Poulin(University of Ottawa), Keith G. Wilson, Taylor Hatchard(McMaster University), Brahm K. Solomon(University of Ottawa), Cheryl Harris(University of Ottawa), Rebecca Small(Memorial University of Newfoundland), Noriyeh Rahbari(Ottawa Hospital), Heather Romanow(Ottawa Hospital), Xinni Song, John Kowal(University of Ottawa), Howard J. Nathan(University of Ottawa), Catherine Smyth(University of Ottawa)

Supportive Care in Cancer

May 18, 2016

10.1007/s00520-016-3243-x

Cited by 88

Related Papers

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

|The Lancet|2020|1.8k

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

|The Lancet Oncology|2021|392

Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice

|Annals of Oncology|2013|250

Psychometric Properties of the Tampa Scale for Kinesiophobia-11 (TSK-11)

|Journal of Pain|2012|229

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

|The Lancet Oncology|2018|216